SCHEMBL20123392

SCHEMBL20123392

NC(=O)N1CCC[C@H]1CO

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
DPP4 P27487 3/20 0.46
DPP8 Q6V1X1 3/20 0.46
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CHRM2 P08172 3/20 0.40
CHRM4 P08173 3/20 0.40
CHRM1 P11229 3/20 0.40
CHRM3 P20309 3/20 0.40
PREP P48147 1/20 0.38
FAP Q12884 1/20 0.38
DPP9 Q86TI2 1/20 0.38
RAB9A P51151 2/20 0.37
SPHK2 Q9NRA0 1/20 0.37
EPHX2 P34913 1/20 0.37
VNN1 O95497 1/20 0.36
PDK2 Q15119 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16561742 1.00 POLB (0.70) POLBL3MBTL1DPP4DPP8MEN1
SCHEMBL2779194 1.00 POLB (0.70) POLBL3MBTL1DPP4DPP8MEN1
SCHEMBL14941549 0.94 L3MBTL1 (0.62) POLBL3MBTL1DPP4DPP8MEN1
SCHEMBL2308749 0.87
Hydrochloric Acid SCHEMBL3130481 0.85 POLB (0.50) POLBL3MBTL1DPP4DPP8
SCHEMBL15808497 0.84 POLB (0.78) POLBL3MBTL1DPP4DPP8MEN1
SCHEMBL27889788 0.83 POLB (0.76) POLBL3MBTL1DPP4DPP8MEN1
SCHEMBL27976413 0.83 POLB (0.76) POLBL3MBTL1DPP4DPP8MEN1
SCHEMBL27906694 0.83 POLB (0.76) POLBL3MBTL1DPP4DPP8MEN1
SCHEMBL3966250 0.82 L3MBTL1 (0.47) POLBL3MBTL1DPP4DPP8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11053495-B2 Multi-targeted single entity conjugates ALNYLAM PHARMACEUTICALS, INC. (US) 2021-07-06 US disclosed
US-20180208927-A1 MULTI-TARGETED SINGLE ENTITY CONJUGATES ALNYLAM PHARMACEUTICALS, INC. (US) 2018-07-26 US disclosed
EP-2620436-B1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG SHIONOGI & CO (JP) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11053495-B2 Multi-targeted single entity conjugates SNRPE, DDX21, RNMT POLB 1210/4885L3MBTL1 369/4885DPP4 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.